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Abstract Current therapy for phenylketonuria (PKU) con-
sists of life-long dietary restriction of phenylalanine (Phe),
which presents problems of adherence for patients. Alter-
native therapies under investigation include, among others,
the use of gene therapy to provide copies of wild-type, non-
mutant, phenylalanine hydroxylase (PAH) enzyme. Expres-
sion of PAH in both liver (the usual metabolic source of this
enzyme) and skeletal muscle is under investigation. Liver
gene therapy, using a viral vector based on the adeno-
associated viruses (AAVs), provided effective clearance of
serum Phe that was sustained for 1 year in some mice. In
order for PAH expression to be effective in skeletal muscle,
the essential metabolic cofactor, tetrahydrobiopterin (BH4),
must also be provided, either by supplementation or gene
therapy. Both these approaches were effective. When
transgenic PKU mice that constitutively expressed PAH in
muscle were given intraperitoneal supplementation with
BH4, this produced (transient) effective clearance of Phe to
normal levels. In addition, use of an AAV vector containing
the genes for PAH, and for two key synthetic enzymes for
BH4, provided substantial and long-lasting correction (more
than 1 year) of blood Phe levels when injected into skeletal
muscle of PKU mice. These two strategies provide
promising treatment alternatives for the management of
PKU in patients.
Abbreviations
AAV adeno-associated virus
BH4 tetrahydrobiopterin
CMV cytomegalovirus
EC Enzyme Commission
ENU N-ethyl-N-nitrosourea
GTP guanosine triphosphate
GTPCH guanosine triphosphate cyclohydrolase I
ITR inverted terminal repeat
OMIM Online Mendelian Inheritance in Man database
PAH phenylalanine hydroxylase
Phe phenylalanine
PKU phenylketonuria
PTPS 6-pyruvoyl-tetrahydropterin synthase
rAAV recombinant adeno-associated virus
SR sepiapterin reductase
WPRE woodchuck hepatitis virus post-transcriptional
element
Introduction
Current treatments for phenylketonuria (PKU; OMIM
262600) consist of life-long dietary restriction of phenylal-
anine (Phe), with or without supplementation by amino acids,
or, for patients responsive to this therapy, treatment with
tetrahydrobiopterin (BH4). Life-long dietary control of Phe
intake is expensive, unpalatable, and difficult for patients to
adhere to, as it severely restricts their lifestyle. It also presents
additional problems for pregnant women, such as the fact that
before and during pregnancy they must strictly maintain a low
Phe diet to prevent foetal damage (the so-called maternal PKU
syndrome). Alternative therapies are, therefore, being sought
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for this condition. Research into PKU has the advantage that
treatment efficacy is easily measured (by the monitoring of
plasma levels of Phe) and, ethically, adult patients who do not
have cognitive problems can give informed consent to
experimental therapies. One such treatment under investiga-
tion is gene therapy for the provision of functioning
phenylalanine hydroxylase (PAH; EC 1.14.16.1) via viral
vectors that are expressed in either liver or muscle. These two
strategies for gene therapy in PKU are discussed below.
The PKU mouse
The mouse model used for testing gene therapy has the
Pahenu2 (‘PKU’) mouse allele bred into the C57Bl/6
background (Ding et al. 2006; Shedlovsky et al. 1993).
This strain was originally produced by chemical mutagen-
esis using N-ethyl-N-nitrosourea (ENU), which produced a
missense mutation in the gene for PAH in exon 7 (F263S),
a common site for mutations in human PAH. The gene is
transcribed to mRNA and the mutated PAH protein is
expressed, but this mutant protein has no enzymatic
activity. This results in hyperphenylalaninaemia in the mice
and a PKU-like syndrome that includes slow growth,
hypopigmentation and maternal PKU syndrome. In wild-
type mice, Phe concentrations are less than 100 µM,
whereas those in PKU mice are between 1,500 µM and
2,500 µM (concentrations are slightly higher in female
mice than in male mice). Phe concentrations can be
determined by collection of a blood spot from the tail vein
on a Guthrie card for tandem mass spectrometry.
Adeno-associated virus as a gene-delivery vector
Early research showed that liver-mediated gene therapy
using, for instance, an adenovirus vector was able to
produce a transient reversal of hypopigmentation in PKU
mice (Nagasaki et al. 1999). However, this response was
limited by an immune reaction to the vector. The adeno-
associated viruses (AAVs) are non-pathogenic viruses, and
as such, they appear to be minimally immunogenic (there
may be pre-existing neutralizing antibodies for the com-
monly used serotype 2) and non-inflammatory. They have
the potential to mediate long-term transgene expression in
both dividing and non-dividing cells. To date, at least 14
serotypes of AAV, and more than 100 variants with
different transduction profiles, have been described (Wu et
al. 2006). The main disadvantages of these viruses as
vectors for gene therapy are their relatively poor efficiency
of transduction and organ specificity.
The wild-type AAV genome comprises inverted terminal
repeats (ITRs) at both ends of the DNA strand, and two
open reading frames, rep and cap. The rep reading frame
contains four overlapping genes encoding Rep proteins that
are required for the normal viral life cycle. The cap reading
frame contains overlapping genes for three capsid proteins.
The ITRs are the only cis-regulatory elements necessary for
DNA replication and integration, so the rep and cap regions
are deleted, and the therapeutic gene and a promoter are
inserted between the ITRs. The resulting vector is thought
to be episomally maintained, or it may be integrated at low
frequency into the host-cell genome at a specific site on
human chromosome 19; random integration is extremely
low as a result of rep and cap deletion.
Liver gene therapy for phenylketonuria
For the construction of a vector for PAH gene transfer, the
full-length mouse Pah complementary DNA (cDNA), a
chicken β-actin (CBA) promoter for that sequence (cyto-
megalovirus enhancer–chicken β-actin promoter) and
woodchuck hepatitis virus post-transcriptional element
(WPRE) were inserted into a parent plasmid comprising
AAV2 ITRs. The resulting plasmid pAAV2-PKU5 was co-
transfected, together with two helper plasmids, into the
human embryonic kidney cell line, 293 T. Recombinant (r)
AAV2-PKU5/8 (serotype 8) vectors were then purified
from harvested cells by caesium chloride (CsCl) gradient
centrifugation, and the vector titre was determined by real-
time quantitative polymerase chain reaction for WPRE
(Ding et al. 2006)
PKU mice were given a single injection of the vector
rAAV2-PKU5/8 (serotype 8) via the portal vein. Both male
and female mice demonstrated phenotypic reversion by re-
pigmentation of their coats within 2–8 weeks of treatment
(Ding et al. 2006). Treated mice also showed dramatic
reductions in plasma Phe concentrations to normal levels
within 2 weeks, and this change was sustained in several
mice for more than 1 year (Fig. 1). Whole-liver extracts
from these mice showed PAH activity to be equivalent to
that of the wild-type mice and showed no signs of toxicity,
hepatocellular carcinoma or immunogenicity due to rAAV-
vector transduction. Quantitative TaqMan® analysis of
WPRE DNA showed only extremely low rates of trans-
duction of other tissues by the PAH vector. Treatment with
an AAV2 serotype 8 vector was also shown to be effective
in managing maternal PKU in mice (Jung et al. 2008).
Relative efficacy of adeno-associated virus serotypes
in producing liver transduction
Three AAV serotypes were tested for their effects in PKU
mice, following intramuscular injection. The AAV2/1
(serotype 1) has a preferential tropism for skeletal muscle;
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AAV2/2 (serotype 2) transduces a wide range of tissue
types, including muscle and liver; and AAV2/8 (serotype 8)
shows selectivity for hepatocytes (Rebuffat et al. 2009) The
serotype 1 vector, AAV2/1-PKU5, produced long-term
effects on blood Phe levels in male mice (1 year; end of
experiment) but less pronounced in female mice (approx-
imately 30 weeks). This might be due to the androgen or
sex-dependent influence on liver transduction by AAV-
vector gene transfer, which is a known phenomenon (for
references see Rebuffat et al. 2009). The serotype 2 vector,
AAV2/2-PKU5, again provided benefits for male mice but
had a limited effect on plasma Phe levels in female mice.
By comparison, the serotype 8 vector, AAV2/8-PKU5,
provided long-term effects on Phe in both male and female
mice, but, similarly to the serotype 1 vector, only a transient
correction was seen in the female mice (approx. 35 weeks).
Two strategies were applied to increase or sustain transgene
expression levels in AAV2-PKU5 treated female mice:
administration of serotype 8 vector to mice previously
treated with the AAV2/1 serotype led to prolonged
therapeutic correction in female mice for a similar duration
as was achieved in male mice. Alternatively, exogenous
supplementation with BH4 cofactor (by intraperitoneal
injection) of AAV2-PKU5 serotype 2 or serotype 8 treated
mice also led to a transient decrease in blood Phe levels.
Muscle gene therapy for phenylketonuria
Skeletal muscle comprises 30–40% of the mass of the
human body, and much of it is easily accessible by
percutaneous techniques (compared with access to the
liver). Skeletal muscle is highly vascularized, and it
contains both dividing and non-dividing cells with long
half-lives, and stable episome expression. This tissue is
therefore a good candidate for gene therapy. Besides PAH,
its essential cofactor BH4 is also not synthesized in muscle
and must be supplied to muscle expressing PAH. Previous-
ly, it has been shown that transgenic PKU engineered to
constitutively express PAH in muscle could clear serum Phe
to normal levels upon intraperitoneal supplementation with
BH4 (Harding et al. 1998).
Production of BH4 with phenylalanine hydroxylase
in skeletal muscle
BH4 is synthesized from guanosine triphosphate (GTP) in at
least three enzymatic steps: GTP cyclohydrolase I (GTPCH)
is the first enzyme in BH4 biosynthesis that catalyses the
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Fig. 1 Liver gene therapy with a serotype 8 adeno-associated virus
(AAV) vector expressing PAH from the CBA promoter produced
profound and long-lasting reductions in serum phenylalanine (Phe)
concentrations in phenylketonuria (PKU) mice. Doses of 5×1012
vector genomes were administered by intraportal injection. The
dashed line indicates the normal level of blood Phe (>0.36 mmol/
l or 6 mg/dl) (for more details see also Ding et al. 2006)
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Fig. 2 Treatment with a three-gene vector, providing phenylalanine
hydroxylase (PAH) and two synthetic enzymes for BH4-corrected
serum phenylalanine (Phe) levels in phenylketonuria (PKU) mice. The
upper part shows the physical map of the recombinant AAV2
serotype 1 vector used, and the lower part shows the kinetic changes
of blood Phe concentration in PKU mice after intramuscular
administration of vector in two different doses. The dashed line
indicates the normal level of blood Phe (>0.36 mmol/l or 6 mg/dl) (for
more details see also Ding et al. 2008)
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formation of 7,8-dihydroneopterin triphosphate from GTP. In
the next step, 6-pyruvoyl-tetrahydropterin synthase (PTPS)
catalyses the conversion of 7,8-dihydroneopterin triphos-
phate to 6-pyruvoyl-tetrahydropterin. Sepiapterin reductase
(SR) then catalyses the final two-step reduction of 6-
pyruvoyl-tetrahydropterin to BH4. In wild-type mice, muscle
levels of PAH, GTPCH, PTPS and total BH4 are all present
at non-detectable levels or are extremely low compared with
those in the liver.(Thöny et al. 2000).
Transgenic PKU mice expressing both PAH and the
BH4-synthetic enzyme, GTPCH, in muscle tissue showed
no BH4 in muscle and, in the absence of its synthesis,
accumulation of neopterin (Ding et al. 2008). Thus, the
introduction of this enzyme was insufficient to provide BH4
synthesis in muscle and reduce plasma Phe concentrations.
Supplementation in these animals with a single dose of BH4
produced a transient reduction in blood Phe (Ding et al.
2008). Similarly, when a two-gene recombinant AAV
vector (serotype 1) expressing genes for PAH and for
GTPCH from the (muscle specific) cytomegalovirus
(CMV) promoter was injected into skeletal muscle in the
PKU mouse, there was little effect on plasma Phe
concentrations (Ding et al. 2008). However, a comparable
three-gene vector containing genes for PAH, GTPCH and
PTPS did provide substantial and long-lasting correction
(more than 1 year) of blood Phe levels when injected into
skeletal muscle of PKU mice (Fig. 2). In these mice, there
were 20–107 vector genomes per diploid genome in foreleg
muscle, the site of the AAV2/1 injection, and 1–2% PAH
activity in muscle, compared with that in liver. There was
some expression of the vector genome in liver, but very low
or no expression in other body tissue, as would be
expected upon injection of an AAV serotype 1 vector with a
tropism for skeletal muscle tissue and expressing the
transgenes from the muscle-specific CMV promoter (Ding
et al. 2008).
Conclusions
Gene therapy using AAV vectors expressed in either the
liver or skeletal muscle provides a promising treatment
alternative for the management of PKU. Such therapy can
provide normalization of serum levels of Phe, phenotypic
reversion and management of maternal PKU in mice. In the
future, optimization of this therapy should concentrate on
the safety and longevity of the process. Thus, viral vectors,
foreign or toxic bacterial DNA sequences and the use of
endotoxins should be avoided. Use of an optimized liver or
muscle promoter should allow the stable, long-term
expression of genes, and life-long expression may require
permanent integration of the exogenous gene into the host
genome, or multiple applications of the therapy.
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